129 related articles for article (PubMed ID: 6420161)
1. Combination chemotherapy and immune capacity in advanced ovarian carcinoma.
ten Berge RJ; Schellekens PT; Hamerlynck JV; Bruning PF
Eur J Cancer Clin Oncol; 1984 Jan; 20(1):91-8. PubMed ID: 6420161
[TBL] [Abstract][Full Text] [Related]
2. Randomised trial comparing two combination chemotherapy regimens (Hexa-CAF vs CHAP-5) in advanced ovarian carcinoma.
Neijt JP; ten Bokkel Huinink WW; van der Burg ME; van Oosterom AT; Vriesendorp R; Kooyman CD; van Lindert AC; Hamerlynck JV; van Lent M; van Houwelingen JC
Lancet; 1984 Sep; 2(8403):594-600. PubMed ID: 6147640
[TBL] [Abstract][Full Text] [Related]
3. The cyclophosphamide, hexamethylmelamine, 5 fluorouracil (CHF) regimen in the treatment of advanced and recurrent ovarian cancer.
Posada JG; Marantz AB; Yeung KY; Smith FP; Delgado G; Edwards BK; Schein PS
Gynecol Oncol; 1985 Jan; 20(1):23-31. PubMed ID: 3917421
[TBL] [Abstract][Full Text] [Related]
4. Hexamethylmelamine, methotrexate and 5-fluorouracil (HMF) for progressive ovarian carcinoma during therapy with cis-platinum, cyclophosphamide +/- doxorubicin.
Carlson JA; Day TG; Botts B; Masterson BJ
Gynecol Oncol; 1985 Oct; 22(2):189-94. PubMed ID: 3932141
[TBL] [Abstract][Full Text] [Related]
5. Hexamethylmelamine-CAF (cyclophosphamide, methotrexate, and 5-FU) and cisplatin-CAF in refractory ovarian cancer.
Sessa C; D'Incalci M; Valente I; Bolis G; Colombo N; Mangioni C
Cancer Treat Rep; 1982 May; 66(5):1233-4. PubMed ID: 6805951
[No Abstract] [Full Text] [Related]
6. Long-term survival in ovarian cancer. Mature data from The Netherlands Joint Study Group for Ovarian Cancer.
Neijt JP; ten Bokkel Huinink WW; van der Burg ME; van Oosterom AT; Willemse PH; Vermorken JB; van Lindert AC; Heintz AP; Aartsen E; van Lent M
Eur J Cancer; 1991; 27(11):1367-72. PubMed ID: 1835850
[TBL] [Abstract][Full Text] [Related]
7. The effect of chemotherapy on lymphocyte subpopulations and cell-mediated cytotoxicity in patients with ovarian carcinoma.
Kohorn EI; Klein-Angerer S
Gynecol Oncol; 1984 Sep; 19(1):60-6. PubMed ID: 6432636
[TBL] [Abstract][Full Text] [Related]
8. Six-drug chemotherapy (hexamethylmelamine, doxorubicin, cisplatin, cyclophosphamide, methotrexate, and 5-FU; CHAMP-5) for ovarian carcinoma: alternating sequences of combination regimens.
Pasmantier MW; Coleman M; Silver RT; Ballard WP
Cancer Treat Rep; 1985 Jun; 69(6):689-93. PubMed ID: 3926310
[TBL] [Abstract][Full Text] [Related]
9. [Treatment of advanced ovarian cancer].
de Gramont A; Krulik M; Pigne A; Brissaud P; Sirinelli A; Hubert D; Zylberait D; Debray J
Sem Hop; 1984 Mar; 60(14):957-60. PubMed ID: 6326283
[TBL] [Abstract][Full Text] [Related]
10. Importance of multiagent chemotherapy regimens in ovarian carcinoma: dose intensity analysis.
Levin L; Simon R; Hryniuk W
J Natl Cancer Inst; 1993 Nov; 85(21):1732-42. PubMed ID: 8411257
[TBL] [Abstract][Full Text] [Related]
11. The case for combination chemotherapy in the treatment of advanced ovarian cancer.
Ozols RF
J Clin Oncol; 1985 Nov; 3(11):1445-7. PubMed ID: 3932603
[No Abstract] [Full Text] [Related]
12. [Chemotherapy in 143 advanced epithelial cancers of the ovary. Experience at the Hôtel-Dieu of Quebec and Hôpital Saint-Antoine (Paris)].
de Gramont A; Drolet Y; Louvet C; Dray C; Krulik M; Pigné A; Lavoie A; Painchaud M; Blouin R; Tessier C
J Gynecol Obstet Biol Reprod (Paris); 1986; 15(1):105-9. PubMed ID: 3084619
[TBL] [Abstract][Full Text] [Related]
13. [Chemotherapy of epithelial ovarian carcinoma].
Bruntsch U; Gallmeier WM
MMW Munch Med Wochenschr; 1983 Nov; 125(44):993-5. PubMed ID: 6417517
[No Abstract] [Full Text] [Related]
14. Advanced ovarian carcinoma: a prospective and randomized clinical trial of cyclophosphamide versus combination cytotoxic chemotherapy (Hexa-CAF).
Carmo-Pereira J; Costa FO; Henriques E; Ricardo JA
Cancer; 1981 Nov; 48(9):1947-51. PubMed ID: 6271386
[TBL] [Abstract][Full Text] [Related]
15. Altretamine.
Hansen LA; Hughes TE
DICP; 1991 Feb; 25(2):146-52. PubMed ID: 1905441
[TBL] [Abstract][Full Text] [Related]
16. Treatment of chemotherapy-resistant advanced ovarian cancer with a combination of cyclophosphamide, hexamethylmelamine, adriamycin, and cis-diamminedichloroplatinum (CHAP).
Bruckner HW; Cohen CJ; Deppe G; Kabakow B; Wallach R; Ratner L; Holland JF
Gynecol Oncol; 1981 Oct; 12(2 Pt 1):150-3. PubMed ID: 6795095
[No Abstract] [Full Text] [Related]
17. The role of hexamethylmelamine in the combination chemotherapy of advanced ovarian cancer: a comparison of hexamethylmelamine, cyclophosphamide, doxorubicin, and cisplatin (H-CAP) versus cyclophosphamide, doxorubicin, and cisplatin (CAP).
Hainsworth JD; Jones HW; Burnett LS; Johnson DH; Greco FA
Am J Clin Oncol; 1990 Oct; 13(5):410-5. PubMed ID: 2121019
[TBL] [Abstract][Full Text] [Related]
18. A randomized study of sequential versus alternating combination chemotherapy in advanced ovarian carcinoma.
Lund B; Hansen M; Hansen HH; Thomsen HK; Sørensen BL; Nielsen NC; Lundvall F
Ann Oncol; 1990; 1(2):134-40. PubMed ID: 2127690
[TBL] [Abstract][Full Text] [Related]
19. Hexamethylmelamine, cyclophosphamide, adriamycin, cis-platinum chemotherapy as initial and second-line treatment of advanced ovarian carcinoma.
Richman CM; Podczaski E; Weiser PA; Herbst AL
Oncology; 1986; 43(1):12-7. PubMed ID: 3079898
[TBL] [Abstract][Full Text] [Related]
20. Current status of systemic chemotherapy in the treatment of advanced ovarian cancer with emphasis on CHAP-5.
Neijt JP; ten Bokkel Huinink WW; van der Burg ME; van Oosterom AT; Vriesendorp R; Pinedo HM
Radiother Oncol; 1984 Jun; 2(1):19-29. PubMed ID: 6438704
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
